Fundraising FoxTCG Crossover
Crossover fundActively deployingPalo Alto · Seed–Late Stage · 25 people tracked
Also known as TCG CROSSOVER MANAGEMENT, LLC
Find your way into TCG Crossover
Sign up to see every warm intro you have to TCG Crossover
- Paths you didn't know you had: your email and LinkedIn already hold routes to the TCG Crossover team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Investment thesis
TCG Crossover is a science-driven crossover investment firm dedicated to advancing disruptive medicines. It focuses on companies developing innovative therapeutics and life-science breakthroughs.
Source: firm website, verified Sep 29, 2026.
Team · 25 people
from the firm's website & public directories
What they invest in
from 24 of 29 portfolio companiesBiotech ×23Healthtech ×16Medical Devices ×13Digital Health ×6AI & Machine Learning ×4Deep Tech ×4Consumer ×1
HQs:United States×14
Who they back
founder profiles across 9 portfolio companiesFounding team size:solo founder×22 founders×44+ founders×3
Investments · 29 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 12024 · 32023 · 12021 · 17 dated
A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders.
BiotechHealthtechNew York, US
Zachary Prensky(Executive Officer, Director)inLauren Stipp(Executive Officer)Mark Panoff(Executive Officer)Heather Turner(President & Chief Executive Officer and Director)Gad Soffer(Chief Operating and Business Officer)Anna Eramo(Chief Medical Officer)
Board seatChen Yu· per SEC Form D
Co-investorsPivotal Life SciencesPontifax Venture CapitalTarnagulla VenturesVida Ventures
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)inPatrick Baeuerle(Co-founder & Advisor)inShulamit Ron-Bigger(Executive Officer)inKyle D. Kuvalanka(Chief Financial Officer)inAkos Czibere(Chief Medical Officer)inPaul L. Feldman(Chief Scientific Officer)in
Co-investorsAndreessen HorowitzEcoR1 CapitalMPM BioImpactMRL Ventures FundPappas CapitalRA Capital+5 more
CG Oncology develops an investigational oncolytic immunotherapy for urologic cancer patients, specifically targeting BCG-unresponsive non-muscle invasive bladder cancer.
BiotechHealthtechMedical Devices
Arthur Kuan(Chairman and Chief Executive Officer)in
Co-investorsDecheng CapitalForesite CapitalLongitude CapitalPalm Drive CapitalRA CapitalACORN BIOVENTURES+3 more
Entrada Therapeutics is a biotech company developing intracellular therapeutics based on its proprietary EEV Platform, aimed at reaching previously inaccessible or undruggable disease-causing targets inside cells.
BiotechHealthtechBoston, US
Natarajan Sethuraman(Executive Officer)inNerissa Kreher(Executive Officer)inKory Wentworth(Executive Officer)inDipal Doshi(Chief Executive Officer)inNatarajan Sethuraman, PhD(President of Research and Development)Nathan J. Dowden(President and Chief Operating Officer)in
Co-investors5AM VenturesAgent CapitalMPM BioImpactMRL Ventures FundRoche Venture FundWellington Management
Upstream Bio is a biotechnology company that sponsors clinical trials to develop products under investigation.
BiotechHealthtechWaltham, US
Rand Sutherland(Chief Executive Officer)inAllison Ambrose(General Counsel)inAaron Deykin(Chief Medical Officer & Head of R&D)inMike Gray(Chief Financial Officer and Chief Operating Officer)Adam Houghton(Chief Business Officer)inStacy Price(Chief Technology Officer)in
Co-investorsOrbiMedAccess IndustriesAccess BiotechnologyBain Capital Life SciencesDecheng CapitalHBM Healthcare Investments+5 more
ADARx is a clinical-stage biotechnology company developing RNA-targeted therapeutics designed to control the expression of disease-driving genes.
BiotechHealthtechMedical DevicesSan Diego, US
Zhen Li(Co-founder, President & CEO)inRui Zhu(Founding Member & Chief Technology Officer)Rob Ackles(Chief People Officer)inRyan Fisk(Chief Financial Officer & Chief Business Officer)inRobert A. MacLeod(Chief Scientific Officer)inChristopher Claeboe(Senior Vice President of Operations)in
Board seatChen Yu· per SEC Form D
Co-investorsBain Capital Life SciencesOrbiMedSR One Capital ManagementLilly Asia VenturesT. Rowe PriceAscenta Capital+3 more
Plexium is a targeted protein degradation company developing small molecule therapeutics for treating diseases with high unmet medical needs using their proprietary DELTA Discovery platform.
AI & Machine LearningBiotechDeep TechSan Diego, US
Michael Martin, Ph.D.(Chief Executive Officer, President)Jorge F. DiMartinoinMichael Martin(President, Chief Executive Officer)inStephen Mullennix(Executive Officer)in
BoardSerge Messerlian(Director)in
Board seatCariad Chester· per SEC Form D
Co-investorsaMoonCRV (Charles River Ventures)DCVC (Data Collective)M VenturesNeotribe VenturesPivotal Life Sciences+3 more
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical Devices
Co-investorsVida VenturesHealthCapJeito CapitalNovo HoldingsOrbiMedPontifax Venture Capital+3 more
Affinia Therapeutics develops genetically engineered adeno-associated virus (AAV) therapies for treating genetic diseases, focusing initially on cardiovascular and central nervous system conditions.
AI & Machine LearningBiotechDeep TechWaltham, US
Luc Vandenberghe(Director)Aaron Tward, M.D., Ph.D.(Scientific Co-Founder)Botond Roska, M.D., Ph.D.(Scientific Co-Founder)Luk Vandenberghe, Ph.D.(Scientific Co-Founder and Adviser, and Board Member)Rami Daoud(Executive Officer)inRick Modi(Chief Executive Officer, Board Member)
Co-investorsAtlas VentureEcoR1 CapitalEight Roads VenturesF-Prime CapitalGV (Google Ventures)New Enterprise Associates (NEA)
Alkeus Pharma develops therapies for retinal diseases, including inherited and neovascular conditions.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Carlos Quezada-Ruiz(Chief Medical Officer)in
Co-investorsBain Capital Life SciencesSofinnova VenturesWellington Management
Arbor develops programmable DNA editors for genetic medicine, aiming to enable functional cures for patients by addressing genetic diseases through bespoke gene editing approaches.
BiotechDigital HealthMedical DevicesCambridge, US
DAVID ARTHUR SCOTT(Executive Officer)inWINSTON XIA YAN(Executive Officer)FENG ZHANG(Director)Feng Zhang, Ph.D.(Arbor Co-founder and Scientific Advisory Board Chair)David Walt, Ph.D.(Arbor Co-founder)David Scott, Ph.D.(Arbor Co-founder)
Co-investorsARCH Venture PartnersIllumina VenturesOno Venture Investment, Inc.Ally Bridge GroupJanus Henderson InvestorsRevelation Partners+4 more
Beacon Therapeutics develops gene therapies for patients with serious diseases that lack or have limited treatment options, including investigational products like laru-zova for genetic conditions.
BiotechDigital HealthMedical Devices
Daniel Chung(Chief Medical Officer)inLance Baldo(Chief Executive Officer)inAbraham Scaria(Chief Scientific Officer)in
Co-investorsAdvent Life SciencesForbionOxford Science Enterprises
Candid develops clear aligner technology and offers remote monitoring services for dental professionals to deliver orthodontic treatment.
ConsumerDigital HealthHealthtechMedical Devices
Nick Greenfield(Founder)in
Co-investorsA-Rod CorpAverin CapitalBessemer Venture PartnersBeyond CapitalF-Prime CapitalFantail Ventures+9 more
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)inKenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)inBernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalLifeSci Venture PartnersOrbiMedSamsara BioCapitalThird Rock VenturesvenBio Partners+2 more
Carmot is a clinical-stage biotechnology company developing novel treatments for obesity and type 2 diabetes through biased receptor agonist compounds.
AI & Machine LearningBiotechDeep TechDigital HealthHealthtechMedical DevicesBerkeley, US
Daniel A. Erlanson(Executive Officer, Director)Stig K. Hansen(Executive Officer, Director)
BoardTim Kutzkey(Director)Larry Lasky(Director)Aetna Wun Trombley(Director)
Co-investorsFrazier Life SciencesHorizons VenturesRA CapitalThe Column Group
Damora Therapeutics develops targeted monoclonal antibody therapies for rare blood disorders, specifically Essential Thrombocythemia and Myelofibrosis driven by mutant calreticulin mutations.
BiotechDigital HealthMedical Devices
Jennifer Jarrett(Chief Executive Officer & Board Director)inSherwin Sattarzadeh(Chief Operating Officer)inBecker Hewes(Chief Medical Officer)
Co-investorsWellington Management
Pioneering a drug discovery method based on tracking the movement of individual proteins in living cells.
Eric Betzig(Founder)Luke Lavis(Founder)Robert Tjian(Founder)Xavier Darzacq(Founder)
Co-investorsEcoR1 CapitalHorizons VenturesLux CapitalThe Column GroupWPSS InvestmentsGeneral Catalyst+1 more
.png)
Korsana develops technology to deliver large-molecule biologic drugs across the blood-brain barrier using transferrin receptor shuttling, aimed at treating neurodegenerative diseases such as Alzheimer's.
BiotechDeep TechHealthtechWaltham, US
Mark Vignola(Chief Financial Officer)inJonathan Violin(President)in
Co-investorsSanofi VenturesWellington ManagementVenrock
Obsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer.
BiotechHealthtech
Peter Barrett(Co-founder & Board Member)inTom Wandless(Scientific Founder)Madan Jagasia(Chief Executive Officer)inParameswaran Hari(Chief Medical Officer)inJulie Feder(Chief Financial Officer)inDana Alexander(Chief Technical Officer)in
Co-investorsAtlas VentureVertex Ventures HCWellington Management
Ollin Biosciences is a clinical-stage biopharmaceutical company that acquires and develops therapies for vision-threatening eye diseases, including wet age-related macular degeneration, diabetic macular edema, and thyroid eye disease.
BiotechMedical Devices
Co-investorsAndreessen HorowitzMonograph Capital Partners
Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.
BiotechHealthtechMedical Devices
Co-investorsAtlas VentureBiotechnology Value FundForbionLightspeed Venture PartnersResearch Corporation Technologies
RayzeBio develops radiopharmaceutical therapies for cancer treatment.
BiotechHealthtechMedical DevicesSan Diego, US
Ken Song(Executive Officer, Director)inBen Hickey(President)inAbhi Bhat, PhD(Senior Vice President, Research & Development)Deborah Charych(Executive Officer)Yi Larson(Director)
BoardAaron Royston(Director)in
Co-investorsLifeSci Venture PartnersSamsara BioCapitalScion Life SciencesSofinnova VenturesvenBio PartnersVersant Ventures+4 more
Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy.
BiotechHealthtech
K. Christopher Garcia(Founder)Susan Molineaux(CEO)inMartin Oft(Chief Scientific Officer)inNaiyer Rizvi(Chief Medical Officer)inGregory(Chief Technical Officer)Geoff(Chief Business Officer)
Co-investorsSamsara BioCapitalThe Column GroupBain Capital Life SciencesCanaan PartnersRA CapitalDeerfield Management Company+2 more
Biotechnology company developing cellular therapies for organ transplantation and autoimmune disorders.
Co-investorsAnjostAvoro Capital AdvisorsLongitude CapitalScion Life SciencesVivo CapitalQiming Venture Partners
AI & Machine LearningBiotechHealthtech
Co-investorsAvoro Capital AdvisorsMedicxiUniQuest Extension Fund (UEF)venBio PartnersJMI Equity
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Ollin Biosciences, Inc.Artios PharmaShoutipharmaVersanis Bio
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 6
5 IPOs · 1 acquisitionsLB PharmaceuticalsNASDAQ: LBRXAktis OncologyNASDAQ: AKTSCG OncologyNASDAQ: CGONEntrada Therapeutics, Inc.NASDAQ: TRDAUpstream BioNASDAQ: UPBVicebioacq. by Sanofi
Portfolio news
latest coverage across their companiesKorsana · finsmes.com · Feb 18, 2026
Affinia Therapeutics · finsmes.com · Oct 8, 2025
Fund performance · per public LP disclosures
as of Nov 2025| Fund | Vintage | Committed | Net IRR | TVPI | DPI |
|---|---|---|---|---|---|
| TCG Crossover FundLPs: Employees' Retirement System of Rhode Island | 2021 | — | 16.4% | 1.42x | 0.71x |
Source: public limited-partner disclosures (CalPERS, CalSTRS). Net IRR / TVPI / DPI as reported by the limited partner; a fund's early-year IRR is an interim estimate (J-curve).
IPO stake values · per SEC filings · 2
Value of this firm's stake in each portfolio company at its IPO price, from the prospectus principal-stockholder table.
| Company | Owned | IPO price | At IPO | Stake value |
|---|---|---|---|---|
| Upstream Bio | 5.4% | $17.00 | Oct 2024 | $47.2M |
| LB Pharmaceuticals | 1.8% | $15.00 | Sep 2025 | $6.2M |
Source: SEC S-1 / 424B prospectus filings. Stake value = shares beneficially owned × the initial public offering price, as disclosed — a market value at IPO, not a return multiple (the firm's original cost is not disclosed).
Public market activity · per SEC filings
what is this? ⓘ6 insider ownership filings (Forms 3/4/5)
at Vor Biopharma Inc. (VOR), Surrozen, Inc./DE (SRZN)
From the firm's own SEC EDGAR filings — stakes and insider roles in public companies, typically portfolio companies after an IPO. Not a portfolio list published by the firm.
Frequently asked questions
- How many investments has TCG Crossover made?
- TCG Crossover has 29 tracked investments, 6 of which have exited, including 2 dated in the last 24 months.
- What stage does TCG Crossover invest at?
- TCG Crossover invests at the Seed, Series A, Series B, Series C, Late Stage stages.
- What sectors does TCG Crossover focus on?
- TCG Crossover focuses on Biotech, Healthtech.
- Where is TCG Crossover located?
- TCG Crossover is headquartered in Palo Alto, US.
- Who does TCG Crossover co-invest with?
- TCG Crossover most often shares deals with Wellington Management, RA Capital, OrbiMed, among 63 tracked co-investors.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
EDBI is the investment platform of Singapore's Economic Development Board and Enterprise Singapore, focusing on high-growth technology companies expanding into Singapore and Asia.
Founders Fund is a venture capital firm that backs technology companies building transformative products.
GV (Google Ventures) is a venture capital firm that has invested in AI and machine learning since its early days, backing more than 100 AI companies across infrastructure, life sciences, and applications.
General Catalyst is a venture capital firm operating as a partnership focused on company building and accelerating the growth of the businesses it backs.